drugset / Trial / NCT02436889

Treatment of Incontinence Without Memory Problems

NCT02436889

Phase 4 Completed 23 enrolled University of California, San Francisco
RandomizedParallel-groupTriple-blindTreatment

Summary

An 8-week randomized, controlled, pilot clinical trial of Mirabegron compared to a standard anticholinergic therapy (Detrol LA) in elderly women with urgency urinary incontinence.

Timeline

Start
2016-02
Primary completion
2017-12
Completion
2018-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Mirabegron Other / unclassified 25 mg Oral
Subject Mirabegron Other / unclassified 50 mg Oral
Comparator Tolterodine Small molecule 4 mg Oral

Indications